We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Global Cord Blood Corporation | NYSE:CO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.9876 | 0 | 01:00:00 |
From May 2022 to May 2024
By Chris Wack
Global Cord Blood Corp. shares were up 15% to $3.42 after the company said Cellenkos Inc. recently got U.S. Food and Drug Administration clearance for its Investigational New Drug application for CK0804.
This clearance allows Cellenkos to initiate a Phase 1b, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.
Global Cord Blood agreed to buy biotechnology company Cellenkos in April. At closing, Global Cord will issue 125 million new shares valued at $11 a share, and pay $664 million in cash.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 17, 2022 12:34 ET (16:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Global Cord Blood Chart |
1 Month Global Cord Blood Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
